person · Reporting owner
Fitzgerald Kevin Joseph
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | CSO & EVP, Head of Research | March 04, 2026 | March 06, 2026 |
| Ovid Therapeutics Inc.OVID · Entity 5411 | Director | April 07, 2026 | April 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,569 |
Ending reported balance
After 2026-03-05 transaction · row 12
12 source rows · reconciled sequenceRow 1 · 2026-03-04 · Sale · Disposed 29 · Balance 21,831 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2026-03-04 · Sale · Disposed 28 · Balance 21,803 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-03-04 · Sale · Disposed 59 · Balance 21,744 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-03-04 · Sale · Disposed 79 · Balance 21,665 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-03-04 · Sale · Disposed 96 · Balance 21,569 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-03-04 · Sale · Disposed 210 · Balance 21,359 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 7 · 2026-03-04 · Sale · Disposed 75 · Balance 21,284 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-03-04 · Sale · Disposed 57 · Balance 21,227 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 9 · 2026-03-05 · Sale · Disposed 124 · Balance 21,103 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.43 to $322.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 10 · 2026-03-05 · Sale · Disposed 233 · Balance 20,870 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.81 to $323.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 11 · 2026-03-05 · Sale · Disposed 148 · Balance 20,722 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.36 to $325.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 12 · 2026-03-05 · Sale · Disposed 153 · Balance 20,569 F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025. F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.01 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| Common StockSEC Table I · non-derivative | Indirectby Managed Account | 537 |
Reported balance
Holding disclosure · report date 2026-03-04 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 537 F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.
F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: This transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted by the Reporting Person on August 14, 2025.
F11: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.43 to $322.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.81 to $323.65. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.36 to $325.01. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F14: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $326.01 to $326.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F15: Reflects shares of ALNY common stock acquired by the Reporting Person under the issuer 401(k) plan as a result of the issuer 401(k) matching contribution program.
Ovid Therapeutics Inc.
Report date April 07, 2026 · Filed April 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,578 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Grant · Acquired 17,578 · Balance 17,578 F1: Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") award issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of an annual cash retainer for service on the Issuer's Board of Directors in the aggregate amount of $45,000. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 199 | $364.83 | $72,601.17 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 12 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,066 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $364.00 to $365.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 47 | $363.55 | $17,086.85 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 11 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,265 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $362.99 to $363.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 73 | $362.38 | $26,453.74 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 10 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,312 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $361.93 to $362.92. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 98 | $361.45 | $35,422.10 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 9 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,385 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $360.90 to $361.89. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 155 | $360.22 | $55,834.10 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 8 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,483 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $359.79 to $360.79. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 85 | $359.14 | $30,526.90 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 7 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,638 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $358.69 to $359.66. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 123 | $358.18 | $44,056.14 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 6 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,723 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $357.68 to $358.68. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 96 | $357.17 | $34,288.32 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 5 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,846 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.63 to $357.63. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 41 | $356.09 | $14,599.69 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 4 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,942 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $356.62 to $356.61. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 42 | $355.16 | $14,916.72 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 3 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,983 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $354.54 to $355.53. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 39 | $353.95 | $13,804.05 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 2 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,025 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $353.53 to $354.41. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| January 11, 2026 Filed Jan 14, 2026 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-26-000011 · edgardoc.xml · nonDerivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,064 F1 · kind: On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of forty (40) percent of the shares subject to the PSU based on the issuer publicly reporting $2.5 billion in annual net product revenue in accordance with GAAP, as determined by the People, Culture and Compensation Committee of the Issuer Board of Directors on January 11, 2026. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionStock Option (right to buy) · Derivative | 8,161 | $0.00 Strike: $119.13 | $0.00 |
DisclosureSEC source: 0001735276-25-000123 · edgardoc.xml · derivative · entry 14 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 839 Underlying: Common Stock · 8,161 shares Expires 2028-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F12 · derivative.exercise_date: This stock option was fully vested and exercisable as of December 1, 2021. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 295 | $463.08 | $136,608.60 |
DisclosureSEC source: 0001735276-25-000123 · edgardoc.xml · nonDerivative · entry 12 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,264 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $462.82 to $463.46. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 323 | $461.96 | $149,213.08 |
DisclosureSEC source: 0001735276-25-000123 · edgardoc.xml · nonDerivative · entry 11 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,559 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $461.50 to $462.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 707 | $460.84 | $325,813.88 |
DisclosureSEC source: 0001735276-25-000123 · edgardoc.xml · nonDerivative · entry 10 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,882 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $460.46 to $461.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 622 | $459.89 | $286,051.58 |
DisclosureSEC source: 0001735276-25-000123 · edgardoc.xml · nonDerivative · entry 9 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,589 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $459.40 to $460.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 794 | $458.41 | $363,977.54 |
DisclosureSEC source: 0001735276-25-000123 · edgardoc.xml · nonDerivative · entry 8 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,211 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $458.01 to $458.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 262 | $457.39 | $119,836.18 |
DisclosureSEC source: 0001735276-25-000123 · edgardoc.xml · nonDerivative · entry 7 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,005 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $457.00 to $457.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 364 | $456.25 | $166,075.00 |
DisclosureSEC source: 0001735276-25-000123 · edgardoc.xml · nonDerivative · entry 6 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,267 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.97 to $456.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 368 | $455.24 | $167,528.32 |
DisclosureSEC source: 0001735276-25-000123 · edgardoc.xml · nonDerivative · entry 5 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,631 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.92 to $455.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 129 | $451.51 | $58,244.79 |
DisclosureSEC source: 0001735276-25-000123 · edgardoc.xml · nonDerivative · entry 4 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,999 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.41 to $451.84. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 96 | $450.09 | $43,208.64 |
DisclosureSEC source: 0001735276-25-000123 · edgardoc.xml · nonDerivative · entry 3 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,128 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 8,168 | $449.00 | $3,667,432.00 |
DisclosureSEC source: 0001735276-25-000123 · edgardoc.xml · nonDerivative · entry 2 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,224 F1 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. Read SEC document |
| November 17, 2025 Filed Nov 19, 2025 21:05 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 8,161 | $119.13 | $972,219.93 |
DisclosureSEC source: 0001735276-25-000123 · edgardoc.xml · nonDerivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,392 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the Reporting Person on August 14, 2025. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 3 | $457.64 | $1,372.92 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 14 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,231 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 122 | $457.43 | $55,806.46 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 13 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,234 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 60 | $455.82 | $27,349.20 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 12 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,356 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.42 to $456.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 203 | $454.84 | $92,332.52 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 11 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,416 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.38 to $455.34. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 273 | $453.77 | $123,879.21 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 10 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,619 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.37 to $454.37. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 555 | $452.69 | $251,242.95 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 9 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,892 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.33 to $453.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 276 | $451.86 | $124,713.36 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 8 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,447 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.31 to $452.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 449 | $450.81 | $202,413.69 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 7 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,723 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.29 to $451.29. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 207 | $449.79 | $93,106.53 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 6 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,172 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.26 to $450.26. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 150 | $448.77 | $67,315.50 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 5 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,379 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $448.25 to $449.24. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 47 | $447.92 | $21,052.24 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 4 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,529 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.21 to $448.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 96 | $446.53 | $42,866.88 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 3 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,576 F3 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of tranches of PSUs granted to the reporting person on February 24, 2021 and March 1, 2024. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $446.19 to $447.19. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 2,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 2 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,672 F2 · kind: On March 1, 2024, the reporting person was granted a PSU under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study in a prevalent indication, as determined by the PC&C Committee on October 1, 2025. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 21:13 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 2,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000114 · edgardoc.xml · nonDerivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,821 F1 · kind: On February 24, 2021, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of four specified performance measures. The shares reported were issued to the reporting person upon vesting of one-quarter of the shares subject to the PSU based on the issuer publicly reporting the initiation of a Phase 3 clinical study of an RNAi therapeutic in development to treat a prevalent disease, as determined by the People, Culture and Compensation (PC&C) Committee of the Issuer Board of Directors on October 1, 2025. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 12 | $455.82 | $5,469.84 |
DisclosureSEC source: 0001735276-25-000088 · edgardoc.xml · nonDerivative · entry 9 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,719 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $455.65 to $456.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 241 | $454.84 | $109,616.44 |
DisclosureSEC source: 0001735276-25-000088 · edgardoc.xml · nonDerivative · entry 8 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,731 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $454.58 to $455.55. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 543 | $454.04 | $246,543.72 |
DisclosureSEC source: 0001735276-25-000088 · edgardoc.xml · nonDerivative · entry 7 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,972 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $453.50 to $454.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 329 | $452.96 | $149,023.84 |
DisclosureSEC source: 0001735276-25-000088 · edgardoc.xml · nonDerivative · entry 6 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,515 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $452.49 to $453.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 103 | $451.99 | $46,554.97 |
DisclosureSEC source: 0001735276-25-000088 · edgardoc.xml · nonDerivative · entry 5 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,844 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $451.48 to $452.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 39 | $450.92 | $17,585.88 |
DisclosureSEC source: 0001735276-25-000088 · edgardoc.xml · nonDerivative · entry 4 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,947 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $450.42 to $451.39. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 90 | $449.92 | $40,492.80 |
DisclosureSEC source: 0001735276-25-000088 · edgardoc.xml · nonDerivative · entry 3 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,986 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $449.21 to $450.16. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 18, 2025 Filed Aug 19, 2025 21:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 39 | $447.98 | $17,471.22 |
DisclosureSEC source: 0001735276-25-000088 · edgardoc.xml · nonDerivative · entry 2 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,076 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of a tranche of restricted stock units granted to the reporting person on March 1, 2024. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $447.53 to $448.45. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 2,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000088 · edgardoc.xml · nonDerivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,115 F1 · kind: On March 1, 2024, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of thirty (30) percent of the shares subject to the PSU based on the achievement of a clinical milestone, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on August 15, 2025. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 7,763 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-25-000077 · edgardoc.xml · nonDerivative · entry 1 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,264 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 71 | $242.93 | $17,248.03 |
DisclosureSEC source: 0001735276-25-000034 · edgardoc.xml · nonDerivative · entry 15 Fitzgerald Kevin Joseph · CIK 0001886431 · CSO & EVP, Head of Research 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,501 F9 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.